Research programme: bicycle peptide therapeutics - AstraZeneca/Bicycle Therapeutics

Drug Profile

Research programme: bicycle peptide therapeutics - AstraZeneca/Bicycle Therapeutics

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Bicycle Therapeutics
  • Developer AstraZeneca; Bicycle Therapeutics
  • Class Peptides
  • Mechanism of Action Matrix metalloproteinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cardiovascular disorders; Metabolic disorders; Respiration disorders

Most Recent Events

  • 01 Dec 2016 Bicycle Therapeutics and AstraZeneca agree to co-develop and co-promote bicyclic peptides in for respiratory, cardiovascular and metabolic diseases
  • 01 Dec 2016 Early research in Cardiovascular disorders, Metabolic disorders and Respiration disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top